Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Core Insights - Royalty Pharma has experienced a transformational year in 2025, marked by significant strategic transactions and strong financial performance [2][3] - The company internalized its external manager, consolidating operations into a single business entity, which is crucial for strategic and financial alignment [2] - Royalty Pharma has executed numerous successful deals throughout the year, resulting in record capital returns to shareholders and a robust financial standing [3] Financial Performance - The company has returned a record amount of capital to shareholders, indicating strong financial health and commitment to shareholder value [3] - Positive momentum is evident in the company's financial results, suggesting a strong outlook as it approaches the end of the year [3] Strategic Developments - The internalization of the external manager is a key strategic move that enhances operational efficiency and aligns the company's business model [2] - The strong pipeline of projects and deals positions the company favorably for continued growth and success in the upcoming year [3]